Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Performance Status Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nighttime Feeding and Morning Endurance Performance

NCT02160873
View directory record Official record
Conditions
Poor Performance Status
Interventions
chocolate milk, flavor-matched placebo
Other
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Phase 1 Interventional

CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT01839981
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
6,8-bis(benzylthio)octanoic acid
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Phase 1Phase 2 Interventional

CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

NCT03699319
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
CPI 613, Oxaliplatin, Irinotecan, 5-flurouracil, Folinic acid
Drug
Lead sponsor
David Bajor, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Jul 23, 2026, 5:31 AM EDT
Recruiting Phase 2 Interventional

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

NCT07322263
View directory record Official record
Conditions
Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma, Carcinoma in Situ (CIS), High-Grade Papillary Bladder Tumors, BCG-Unresponsive Bladder Cancer, Ta Stage Bladder Cancer, T1 Stage Bladder Cancer, BCG-Refractory Bladder Cancer, High-Risk NMIBC, Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)
Interventions
Intravesical Gemcitabine and Docetaxel
Drug
Lead sponsor
Michael A. O'Donnell
Other
Eligibility
18 Years to 99 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 23, 2026, 5:31 AM EDT
Recruiting Phase 2 Interventional

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

NCT04253964
View directory record Official record
Conditions
Nonsmall Cell Lung Cancer, Performance Status
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Nab paclitaxel, Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13), QLQ-C30 Global Health/Quality of Life Questionnaire, COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes, Pemetrexed
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 23, 2026, 5:31 AM EDT
Completed No phase listed Observational

Evaluating the Use of Wearable Biosensors and PROs to Assess Performance Status in Patients With Cancer

NCT02659358
View directory record Official record
Conditions
Neoplasms
Interventions
Fitbit Charge HR®
Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Phase 3 Interventional

Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)

NCT00040885
View directory record Official record
Conditions
Anorexia, Cachexia, Fatigue, Lung Cancer
Interventions
infliximab, docetaxel, placebo
Biological · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
188
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 116 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Not applicable Interventional

Do Self-Rated Performance Status Scores Correlate With Health-Care-Provider-Scores?

NCT00735111
View directory record Official record
Conditions
Cancer
Interventions
Karnofsky Performance Status Score
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Jul 23, 2026, 5:31 AM EDT
Active, not recruiting No phase listed Observational

A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

NCT07567352
View directory record Official record
Conditions
Non-Small-Cell Lung, ALK-positive Advanced NSCLC, ALK-positive Non-small-cell Lung Cancer, ALK-positive NSCLC
Interventions
lorlatinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Phase 2 Interventional

Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00276588
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2010 · Synced Jul 23, 2026, 5:31 AM EDT
Terminated Phase 4 Interventional Results available

Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)

NCT02695290
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, ErbB Receptors
Interventions
Afatinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Fountain Valley, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00798603
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, carboplatin, pemetrexed disodium
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
70 Years to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
217
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 140 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Not applicable Interventional

Effect Of Acute Inflammatory Mediators On Functional Limitations In Patients With Acute Respiratory Failure

NCT01707303
View directory record Official record
Conditions
Acute Respiratory Failure
Interventions
Early ICU rehabilitation strategies, Usual Care
Other
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00661193
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, erlotinib hydrochloride, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
124
States / cities
Little Rock, Arkansas • Antioch, California • Berkeley, California + 90 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

NCT02879617
View directory record Official record
Conditions
Non-Small Cell Lung Cancer NSCLC
Interventions
durvalumab
Drug
Lead sponsor
Academic Thoracic Oncology Medical Investigators Consortium
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3

NCT02426658
View directory record Official record
Conditions
Stage IV Non-Small Cell Lung Cancer
Interventions
Laboratory Biomarker Analysis, Pemetrexed Disodium, Quality-of-Life Assessment
Other · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Jul 23, 2026, 5:31 AM EDT
Terminated Phase 1 Interventional

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

NCT03963414
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
Durvalumab + Tremelimumab in combination with carboplatin and etoposide, Durvalumab in combination with carboplatin and etoposide
Combination Product
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00124618
View directory record Official record
Conditions
Lung Cancer
Interventions
cetuximab, radiation therapy
Biological · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
175
States / cities
Scottsdale, Arizona • Hollywood, Florida • Jacksonville, Florida + 107 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Phase 1 Interventional

Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status

NCT00986297
View directory record Official record
Conditions
Lung Cancer
Interventions
hypofractionated radiation therapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
2
States / cities
Stanford, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Jul 23, 2026, 5:31 AM EDT
Terminated No phase listed Observational

Feasibility Study: Comparison of Performance Status With Objective Physical Activity Monitors

NCT01063400
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Observation
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vitamin D2, Muscle Damage, NASCAR Pitcrew

NCT01825616
View directory record Official record
Conditions
Muscle Function, Muscle Soreness, Vitamin D Status
Interventions
Vitamin D2 mushroom powder, Placebo
Dietary Supplement · Other
Lead sponsor
Appalachian State University
Other
Eligibility
20 Years to 40 Years · Male only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
3
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

NCT00085839
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Tarceva (Trademark) (erlotinib HCl, OSI-774), Combination carboplatin and paclitaxel
Drug
Lead sponsor
OSI Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
19
States / cities
Greenbrae, California • San Diego, California • Fort Lauderdale, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Not applicable Interventional Results available

Synergizing Home Health Rehabilitation Therapy

NCT05411393
View directory record Official record
Conditions
Frailty, Frail Elderly, Occupational Therapy, Activities of Daily Living, Home Health Care, Functional Status, Physical Functional Performance, Rehabilitation, Treatment Outcome, Health Services for the Aged
Interventions
ADL-enhanced program, Usual home health rehabilitation therapy
Other
Lead sponsor
University of Florida
Other
Eligibility
65 Years to 100 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma

NCT00193479
View directory record Official record
Conditions
Non-Hodgkins Lymphoma
Interventions
Cyclophosphamide, Mitoxantrone, Vincristine, Prednisone, Rituximab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
2
States / cities
Fort Myers, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Jul 23, 2026, 5:31 AM EDT